Cannabis Rescheduling Could Save Dispensaries $800K a Year: The 280E Tax Relief Explained

The single most financially punishing regulation facing legal cannabis businesses in America isn't a state law or a licensing fee — it's a line in the federal tax code written in 1982.

Section 280E of the Internal Revenue Code prevents businesses that traffic in Schedule I or Schedule II controlled substances from deducting ordinary business expenses like rent, payroll, utilities, and marketing from their federal taxes. For cannabis operators, this has meant effective tax rates of 60-80% in some cases.

But with President Trump's December 2025 executive order directing the rescheduling of cannabis from Schedule I to Schedule III now moving through the federal rulemaking process, the industry is staring at what could be its biggest financial turning point ever.

Quick Answer: If cannabis moves from Schedule I to Schedule III, the 280E tax penalty automatically disappears — saving the typical dispensary $268,000-$800,000 per year and unlocking up to $2.2 billion in industry-wide annual cash flow.

Key Takeaways

Industry estimates suggest typical dispensaries could save $268,000-$800,000 annually once 280E relief takes effect
Section 280E has cost the cannabis industry tens of billions in excess taxes by preventing deduction of ordinary business expenses
Rescheduling cannabis from Schedule I to Schedule III would automatically eliminate the 280E tax penalty
President Trump's December 2025 executive order directed expedited completion of the rescheduling process
The IRS has not yet issued guidance on whether relief applies immediately, retroactively to the tax year, or only to future tax years

What Is Section 280E and Why Does It Matter?

What is Section 280E? An IRS code provision enacted in 1982 that bars businesses dealing in Schedule I or Schedule II controlled substances from deducting normal business expenses like rent, payroll, utilities, and marketing from their federal taxes.

Section 280E was enacted in 1982 after a convicted drug dealer named Jeffrey Edmondson successfully argued in tax court that he should be able to deduct his business expenses — including the cost of the drugs he sold. Congress responded by creating 280E, which denies standard business deductions to any enterprise dealing in Schedule I or II substances.

For decades, this was a provision aimed at illegal drug operations. But when states began legalizing cannabis — starting with Colorado and Washington in 2012 — the provision became a financial albatross around the neck of state-legal operators.

The Math That Crushes Cannabis Businesses

A typical dispensary might generate $3 million in annual revenue with $2.4 million in operating expenses, leaving $600,000 in gross profit. In a normal business, federal taxes would apply only to that profit.

Under 280E, however, the company can only deduct the cost of goods sold (COGS) — not rent, not employee wages, not marketing, not insurance. The result is a federal tax bill calculated on a vastly inflated income figure.

Industry analysts estimate that 280E has cost the legal cannabis industry tens of billions of dollars in cumulative excess taxation since state legalization began.

How Rescheduling to Schedule III Eliminates 280E

The connection between rescheduling and tax relief is straightforward: Section 280E only applies to businesses dealing in Schedule I and Schedule II substances.

What is Schedule III? A mid-level federal drug classification that includes drugs like ketamine, anabolic steroids, and Tylenol with codeine. Schedule III substances are considered to have moderate-to-low potential for dependence.

If cannabis moves to Schedule III, the 280E restriction automatically falls away. President Trump's executive order, signed December 18, 2025, directed Attorney General Pamela Bondi to "expedite completion" of the rescheduling rulemaking process. The rule is widely expected to be finalized in the first half of 2026.

What Becomes Deductible

Once rescheduling takes effect, cannabis businesses will be able to deduct the full range of ordinary and necessary business expenses:

Rent and lease payments
Employee wages and benefits
Marketing and advertising costs
Insurance premiums
Professional services (legal and accounting fees)
Equipment depreciation

The Dollar Impact: How Much Will Businesses Save?

Industry analysis puts the financial impact in stark terms.

Individual Business Savings

According to estimates compiled by cannabis financial analysts, the typical dispensary could save approximately $268,000 per year in federal taxes once 280E relief takes effect. Higher-volume operations could see annual savings closer to $800,000 per location.

Industry-Wide Impact

At the industry level, removing 280E could unlock between $1.6 billion and $2.2 billion in incremental after-tax cash flow annually across the U.S. cannabis industry. That's money that can be reinvested in operations, used to lower consumer prices, directed toward employee compensation, or returned to investors.

What are multistate operators (MSOs)? Cannabis companies licensed to operate in multiple states. Major MSOs like Green Thumb Industries, Trulieve, and Curaleaf operate dozens or hundreds of locations and stand to see transformative aggregate savings from 280E relief.

Market Reaction

The stock market has already begun pricing in this expectation. Village Farms International has seen its stock price surge 371% year-to-date, driven largely by rescheduling optimism. Green Thumb and Trulieve have also seen significant gains.

The Timing Question: When Does Relief Actually Kick In?

One of the most important — and still unresolved — questions is exactly when 280E relief becomes effective. Tax law experts have identified three possible scenarios.

Scenario 1: Immediate Relief

Relief applies immediately upon publication of the final rescheduling rule. Cannabis businesses could begin taking deductions for the current tax year as soon as the rule is published in the Federal Register.

Scenario 2: Retroactive to Tax Year

Relief applies retroactively to the beginning of the tax year in which rescheduling occurs. If the rule is finalized in mid-2026, businesses could potentially claim deductions for the entire 2026 tax year.

Scenario 3: Future Tax Years Only

Under the most conservative interpretation, relief only applies to tax years beginning after rescheduling is finalized. Businesses wouldn't see the benefit until their 2027 tax filings.

What to Expect

The IRS has not yet issued formal guidance on the timing question. Some companies are adjusting their estimated quarterly tax payments in anticipation of relief, while others are taking a more conservative wait-and-see approach.

Adding complexity, the IRS recently disputed a cannabis company's argument that 280E shouldn't apply because marijuana doesn't fall "within the meaning of" a Schedule I drug. This suggests the IRS will enforce 280E up until the moment rescheduling is formally completed.

Beyond Taxes: What Else Rescheduling Changes

While 280E relief dominates the business conversation, rescheduling to Schedule III carries several other significant implications.

Research

Schedule III status removes major barriers to federally funded cannabis research. Currently, researchers must navigate a complex approval process involving the DEA, FDA, and NIDA. Schedule III status would streamline this process significantly, potentially accelerating clinical trials and scientific understanding.

Banking

What is the SAFE Banking Act? A federal bill that would let banks serve cannabis businesses without fear of prosecution. It remains stalled in Congress, but rescheduling reduces perceived regulatory risk for financial institutions.

While rescheduling doesn't directly solve the cannabis banking problem, it does reduce the perceived regulatory risk. Some banks and credit unions may become more willing to serve cannabis businesses once the product is no longer classified alongside heroin and LSD.

Investment

Rescheduling could open the door for cannabis companies to eventually list on major exchanges like the NYSE and NASDAQ. Currently, U.S.-based plant-touching cannabis companies are limited to the OTC markets or Canadian exchanges. Schedule III status, combined with 280E relief, could make these companies attractive enough for institutional investors.

What the Industry Should Do Right Now

For cannabis operators preparing for rescheduling, experts recommend several immediate steps.

Model the financial impact — Work with tax advisors to project 280E relief under each timing scenario
Document all non-deductible expenses — Be ready to claim deductions as soon as relief applies
Shore up accounting systems — Many cannabis companies have operated with lean financial infrastructure because deductions were irrelevant under 280E. Detailed, well-organized financial records will be essential
Maintain conservative financial planning — While rescheduling is widely expected in 2026, the rulemaking process isn't complete and legal challenges remain possible

The prudent approach is conservative financial planning with upside optionality.

Frequently Asked Questions

Q: What is 280E and how does it affect cannabis businesses?

Section 280E is a federal tax code provision that prevents businesses dealing in Schedule I or II controlled substances from deducting ordinary business expenses. For cannabis companies, this means they can't deduct rent, payroll, marketing, or other standard costs — resulting in effective tax rates of 60-80%.

Q: How much money will cannabis businesses save from rescheduling?

A typical dispensary could save $268,000-$800,000 per year. At the industry level, removing 280E could unlock $1.6-$2.2 billion in annual cash flow across the U.S. cannabis industry.

Q: When will 280E relief actually take effect?

The timing remains uncertain. It could apply immediately upon rescheduling, retroactively to the beginning of the 2026 tax year, or only to future tax years starting in 2027. The IRS has not yet issued guidance, and tax attorneys advise preparing for any scenario.

Q: Does rescheduling make cannabis federally legal?

No. Rescheduling from Schedule I to Schedule III means cannabis would be classified alongside drugs like ketamine and Tylenol with codeine. It would still be a controlled substance — but with significantly less restriction and, critically, without the 280E tax penalty.

Q: How does rescheduling affect consumers?

Indirectly but significantly. Businesses saving on taxes can reinvest in operations, improve products, and potentially lower consumer prices. Rescheduling also opens the door for more research, better banking access, and eventual listing on major stock exchanges.

Explore More on Budpedia — Find dispensaries near you, browse strain reviews, or read more guides & education.